G lucagon‐like peptide‐1 analogues in monogenic syndromic obesity: Real‐world data from a large cohort of Alström syndrome patients
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15398 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Sadaf Ali und 6 weiteren Autor:innen. Beteiligte Einrichtung: University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Alstrom Syndrome. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Big Lottery Fund grant.
Abstract (Originalsprache)
Aim
To examine the real‐world efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in monogenic obesity in patients with Alström syndrome (ALMS).
Methods
We screened 72 UK adult patients with ALMS and offered treatment to 34 patients meeting one of the following criteria: body mass index of 25 kg/m 2 or higher, insulin resistance, suboptimal glycaemic control on antihyperglycaemic medications or non‐alcoholic fatty liver disease.
Results
In total, 30 patients, with a mean age of 31 ± 11 years and a male to‐female ratio of 2:1, completed 6 months of treatment with GLP‐1 RAs either in the form of semaglutide or exenatide. On average, treatment with GLP‐1 RAs reduced body weight by 5.4 ± 1.7 (95% confidence interval [CI] 3.6‐7) kg and HbA1c by 12 ± 3.3 (95% CI 8.7‐15.3) mmol/mol, equating to 6% weight loss ( P < .01) and 1.1% absolute reduction in HbA1c ( P < .01). Significant improvements were also observed in serum total cholesterol, triglycerides, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol and alanine aminotransferase. The improvement of metabolic variables in our cohort of monogenic syndromic obesity was comparable with data for polygenic obesity, irrespective of weight loss.
Conclusions
Data from our centre highlight the non‐inferiority of GLP‐1 RAs in monogenic syndromic obesity to the available GLP‐1 RA‐use data in polygenic obesity, therefore, these agents can be considered as a treatment option in patients with ALMS, as well as other forms of monogenic obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
- Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
- Torbay and South Devon NHS Foundation Trust, Torquay, Torbay, UK.
ORCID-Profile: Sadaf Ali, Tarekegn Geberhiwot
Förderung
- Big Lottery Fund grant
Zitieren
APA
Ali, S., Baig, S., Wanninayake, S., da Silva Xavier, G., Dawson, C., Paisey, R., & Geberhiwot, T. (2024). G lucagon‐like peptide‐1 analogues in monogenic syndromic obesity: Real‐world data from a large cohort of Alström syndrome patients. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15398
Vancouver
Ali S, Baig S, Wanninayake S, da Silva Xavier G, Dawson C, Paisey R, et al. G lucagon‐like peptide‐1 analogues in monogenic syndromic obesity: Real‐world data from a large cohort of Alström syndrome patients. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15398
BibTeX
@article{Ali2024,
author = {Ali, Sadaf and Baig, Shanat and Wanninayake, Subadra and da Silva Xavier, Gabriela and Dawson, Charlotte and Paisey, Richard and Geberhiwot, Tarekegn},
title = {G lucagon‐like peptide‐1 analogues in monogenic syndromic obesity: Real‐world data from a large cohort of Alström syndrome patients},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15398}
}
EUVIMED